Tu, Hsin-Fang
Wong, Margaret
Tseng, Ssu-Hsueh
Ingavat, Nattha
Olczak, Pola
Notarte, Kin Israel
Hung, Chien-fu
Roden, Richard B.S.
Funding for this research was provided by:
HERA Ovarian Cancer Foundation (Marilyn “Rexy” Usinowicz grant)
National Cancer Institute, USA (P50CA098252, P50CA228991)
Emerson Foundation (20200115162425)
Congressionally Directed Medical Research Programs (OC210370)
Article History
Received: 30 May 2023
Accepted: 12 December 2023
First Online: 16 January 2024
Declarations
:
: No human subjects research was performed. For animal studies, all procedures were performed according to approved protocols by the Johns Hopkins Medical Institutions Animal Care and Use Committee and the National Institutes of Health.
: Not applicable.
: The L1-RG1-VLP technology covered by US patent US14/875,374 “Papillomavirus-like particles (VLP) as broad spectrum human papillomavirus (HPV) vaccines” (Inventors RBSR, Reinhard Kirnbauer, Christina Schellenbacher) is owned by Johns Hopkins University and licensed exclusively to Pathovax LLC. RBSR is a member of the Pathovax LLC Scientific Advisory Board member, and owns equity, and is entitled to roylaties. This arrangement has been reviewed and approved by the Johns Hopkins University in accordance with its conflict of interest policies.